Prevail trial

Introduction

Study characteristics:

• 1700 men with metastatic prostate cancer who had received androgen-deprivation therapy but not chemotherapy
• randomized controlled study

Treatment:

• daily enzalutamide (an androgen-receptor antagonist) vs placebo.

Results:

• at 12 months, radiographic progression-free survival was higher in the enzalutamide group (65% vs 14%)

More general terms

• clinical trial